3. As of noon trading, Illumina ( ILMN) is down $1.50 (-2.8%) to $52.21 on light volume Thus far, 486,932 shares of Illumina exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $51.24-$53.29 after having opened the day at $53.11 as compared to the previous trading day's close of $53.71. Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $6.4 billion and is part of the drugs industry. The company has a P/E ratio of 74.6, above the S&P 500 P/E ratio of 17.7. Shares are up 76.2% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Illumina a buy, 1 analyst rates it a sell, and 7 rate it a hold. TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report now. EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Community Health Systems may close its $7.6 billion acquisition of Health Management Associates, but with the uncertainties of a new healthcare law and the merger partners' own legal problems, it needed good timing to put reasonable financing in place.